Rheumatological Diseases

2021 ◽  
Author(s):  
Irvin J. Huang ◽  
Jenna L. Thomason ◽  
Alison M. Bays
Keyword(s):  
Rheumatological Diseases

scholarly journals Endocrine Disorders in Autoimmune Rheumatological Diseases: A Focus on Thyroid Autoimmune Diseases and on the Effects of Chronic Glucocorticoid Treatment

Endocrines ◽  
2021 ◽  
Vol 2 (3) ◽  
pp. 171-184
Author(s):  
Filippo Egalini ◽  
Mirko Parasiliti Caprino ◽  
Giulia Gaggero ◽  
Vincenzo Cappiello ◽  
Jacopo Giannelli ◽  
...  
Keyword(s):  
Immune System ◽  
Autoimmune Diseases ◽  
Genetic Predisposition ◽  
Endocrine Disorders ◽  
Processed Foods ◽  
Glucocorticoid Treatment ◽  
Environmental Causes ◽  
Main Effects ◽  
Rheumatological Diseases ◽  
Iatrogenic Cushing’S Syndrome

Autoimmune rheumatological diseases’ incidence and prevalence have risen over the last decades and they are becoming increasingly important worldwide. Thyroid autoimmune diseases share with them an imbalance in the immune system that lead to a pro-inflammatory environment. Usually this is the result of a multi-factorial process. In fact, it includes not only a possible genetic predisposition, but also environmental causes like microbiota dysbiosis, diet rich in processed foods, exposure to toxicants and infections. However, many aspects are currently under study. This paper aims to examine the factors that participate in the developing of rheumatological and thyroid autoimmune diseases. Moreover, as glucocorticoids still represent a leading treatment for systemic autoimmune rheumatological diseases, our secondary aim is to summarize the main effects of glucocorticoids treatment focusing on iatrogenic Cushing’s syndrome and glucocorticoids’ withdrawal syndrome.

Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases

2017 ◽  
Vol 77 (2) ◽  
pp. 165-174 ◽  
Author(s):  
Jonathan Kay ◽  
Monika M Schoels ◽  
Thomas Dörner ◽  
Paul Emery ◽  
Tore K Kvien ◽  
...  
Keyword(s):  
English Language ◽  
Task Force ◽  
Level Of Evidence ◽  
Conference Abstract ◽  
Consensus Recommendations ◽  
American College Of Rheumatology ◽  
Published Evidence ◽  
Grade Of Recommendation ◽  
Scientific Meetings ◽  
Rheumatological Diseases

The study aimed to develop evidence-based recommendations regarding the evaluation and use of biosimilars to treat rheumatological diseases. The task force comprised an expert group of specialists in rheumatology, dermatology and gastroenterology, and pharmacologists, patients and a regulator from ten countries. Four key topics regarding biosimilars were identified through a process of discussion and consensus. Using a Delphi process, specific questions were then formulated to guide a systematic literature review. Relevant English-language publications through November 2016 were searched systematically for each topic using Medline; selected papers and pertinent reviews were examined for additional relevant references; and abstracts presented at the 2015 and 2016 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) annual scientific meetings were searched for those about biosimilars. The experts used evidence obtained from these studies to develop a set of overarching principles and consensus recommendations. The level of evidence and grade of recommendation were determined for each. By the search strategy, 490 references were identified. Of these, 29 full-text papers were included in the systematic review. Additionally, 20 abstracts were retrieved from the ACR and EULAR conference abstract databases. Five overarching principles and eight consensus recommendations were generated, encompassing considerations regarding clinical trials, immunogenicity, extrapolation of indications, switching between bio-originators and biosimilars and among biosimilars, and cost. The level of evidence and grade of recommendation for each varied according to available published evidence. Five overarching principles and eight consensus recommendations regarding the evaluation and use of biosimilars to treat rheumatological diseases were developed using research-based evidence and expert opinion.

scholarly journals Rheumatological Diseases in Denim Sandblasters with Silicosis: What Should Pulmonologists Look for?

2020 ◽  
Vol 21 (6) ◽  
pp. 446-450
Author(s):  
Elif Altundas Hatman ◽  
◽  
Duygu Acar Karagul ◽  
Zeki Kilicaslan ◽  
◽  
...  
Keyword(s):  
Rheumatological Diseases

scholarly journals Rheumatological diseases and cancer: the hidden variable of radiation exposure

2014 ◽  
Vol 73 (12) ◽  
pp. 2065-2068 ◽  
Author(s):  
Eugenio Picano ◽  
Richard Semelka ◽  
James Ravenel ◽  
Marco Matucci-Cerinic
Keyword(s):  
Radiation Exposure ◽  
Hidden Variable ◽  
Rheumatological Diseases

169-P: The DRB1* 04 gene as marker in some rheumatological diseases

2007 ◽  
Vol 68 (1) ◽  
pp. S100
Author(s):  
Victoriano J. Leon ◽  
Alberto J. Leon ◽  
Susana Gomez Castro ◽  
Carlos A. Montiya
Keyword(s):  
Rheumatological Diseases

Drug Resistance in Rheumatological Diseases

2021 ◽  
pp. 461-474
Author(s):  
Hassan Waqar ◽  
Ammar Arshad ◽  
Muhammad Asad Raza ◽  
Mohammad Qamar Nasir ◽  
Ahmed Shams Nasir ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Rheumatological Diseases

Polymyalgia rheumatica

2020 ◽  
pp. 4584-4590
Author(s):  
Bhaskar Dasgupta ◽  
Eric L. Matteson
Keyword(s):  
Polymyalgia Rheumatica ◽  
Acute Phase Response ◽  
Inflammatory Arthritis ◽  
Significant Proportion ◽  
Infectious Agent ◽  
Abrupt Onset ◽  
Inflammatory Rheumatic Diseases ◽  
Reactive Protein ◽  
The Common ◽  
Rheumatological Diseases

Polymyalgia rheumatica is one of the common inflammatory rheumatic diseases of older people. It overlaps with inflammatory arthritis and large-vessel vasculitis, particularly giant cell arteritis. Pathogenesis is unclear and may involve recognition of an infectious agent by aberrantly activated dendritic cells. Polymyalgia rheumatica is characterized by abrupt-onset pain and morning stiffness of the shoulder and pelvic girdle muscles, with an acute phase response (elevated erythrocyte sedimentation rate and/or C-reactive protein). Evaluation can be challenging, as many clinical and laboratory features may also be present in other conditions, including other rheumatological diseases, infection, and neoplasia. The mainstay of therapy is glucocorticoids. Adjunctive therapy can be initiated early in the disease course in patients with high risk of glucocorticoid-related side effects, severe or relapsing disease, or poor or ill sustained response to glucocorticoids. The response to standardized therapy is heterogeneous, and a significant proportion of patients do not respond completely.

Sign in / Sign up

Export Citation Format

Share Document